Mycovia Pharmaceuticals

10:30 AM - 10:45 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
At Mycovia, we are passionate about developing novel drugs in areas of unmet medical need, with an initial focus in women’s health.

Our lead product candidate, VT-1161, is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a debilitating chronic condition that affects millions of women worldwide. More commonly known as a chronic yeast infection, RVVC can severely impact a woman’s physical and emotional well being, and results in billions of dollars in lost productivity.

With no FDA-approved treatments for RVVC in the U.S., there are limited treatment options available for women who experience three or more yeast infections a year. Mycovia currently has three Phase 3 clinical studies being conducted to evaluate VT-1161 for the treatment of RVVC and is on path to be the first FDA-approved treatment for this debilitating disease.
Company Type:
Company Website:
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
VT-1161
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
CEO
Mycovia Pharmaceuticals